Hetlioz tasimelteon regulatory update

EMA’s CHMP recommended approval for Hetlioz tasimelteon from Vanda to treat non-24-hour sleep-wake disorder in blind adults. FDA approved the melatonin MT1 and MT2 receptor agonist in January. The pro...